Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/necrosis in residual masses. Post-therapy [18F]FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in the setting of clinical trials.
|Title of host publication||Nuclear Oncology|
|Subtitle of host publication||From Pathophysiology to Clinical Applications|
|Publisher||Springer International Publishing|
|Number of pages||44|
|State||Published - Oct 4 2022|
- Hodgkin lymphoma
- Non-Hodgkin lymphoma